Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy

Daochun Sun¹, Michael A. Tainsky¹,² and Ramsi Haddad²–⁴

¹Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Wayne State University, Detroit, MI 48201. ²Department of Oncology, Wayne State University School of Medicine, Wayne State University, Detroit, MI 48201. ³Laboratory of Translational Oncogenomics, National Oncogenomics and Molecular Imaging Center (NOMIC), Karmanos Cancer Institute, Detroit, MI 48201. ⁴Current Address: Results Genomics, 4352 Showdown Avenue, Windsor, Ontario, N9G-3C2, Canada. Corresponding author email: ramsi.haddad@resultsgenomics.com

Abstract: Malignant peripheral nerve sheath tumors (MPNST) are a type of soft tissue sarcoma that can be associated with germline mutations in Neurofibromatosis type 1 (NF1) or may occur sporadically. Although the etiology of MPNST is poorly understood, it is clear that a loss of function of the NF1 gene, encoding a Ras-GAP, is an important factor in the tumorigenesis of the inherited form of MPNST. Tumor latency in NF1 patients suggests that additional mutational events are probably required for malignancy. In order to define oncogene mutations associated with 5 MPNST cell lines, we assayed the 238 most frequent mutations in 19 commonly activated oncogenes using mass spectroscopy-based analysis. All 238 mutation sites in the assayed oncogenes were determined to harbor only wild-type sequences. These data suggest that hyperactive Ras resulting from the loss function of neurofibromin may be sufficient to set up the direction of malignant transformation of Schwann cells to MPNST.

Keywords: MPNST, Ras-GAP, Neurofibromatosis, oncogene mutation

Translational Oncogenomics 2012:5 1–7
doi: 10.4137/TOG.S8830

This article is available from http://www.la-press.com.

© the author(s), publisher and licensee Libertas Academica Ltd.

This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Introduction

Malignant peripheral nerve sheath tumor (MPNST) is a type of soft tissue sarcoma that develops from the peripheral nerves, preexisting benign neurofibromas, or Schwann cells. Approximately 50% of MPNST occurs in the setting of NF1 genetic disease (OMIM ID #162200) with the remainder occurring sporadically. The lifetime risk for NF1 patients to develop a MPNST is 8%–13%, and the five-year survival rate is 20%–50%. NF1 patients are most frequently diagnosed with MPNST in the third and fourth decades of life whereas the sporadic form of MPNST is most frequently diagnosed in the sixth and seventh decades of life.1

MPNST is thought to arise from the accumulation of additional genetic events in precursor Schwann cells. Neurofibromas are benign peripheral nerve sheath tumors and may or may not be associated with the NF1 gene. Plexiform neurofibromas are almost exclusively NF1-associated and easily progress to MPNST. Mouse model studies have indicated a heterozygous NF1 state was required for the Schwann cell derived plexiform neurofibroma formation and tumor microenvironment.2 Localized cutaneous neurofibroma and diffuse cutaneous neurofibroma are 90% sporadic and have lower malignant potential.3 Whether the status of the NF1 gene is the only requirement for malignancy remains questionable, however.

In NF1-associated neurofibroma, Ras signaling is hyperactive because of the loss of function of neurofibromin (encoded by NF1 gene) which normally acts as a Ras GTPase activating protein (GAP). Whereas other cell types exhibit oncogene-induced senescence after activation of Ras due to missense mutations at amino acids 12,13, and 61, inactivation of NF1 in neurofibromas typically results in a transitory growth arrest. Eventually escaping this growth limitation gives rise to MPNSTs.4 The mechanism behind this escape from oncogene-induced senescence it is not completely understood. A genetic study investigating neurofibroma occurrence in 175 patients from 48 pedigrees (including 6 monozygotic twins) suggested that there was highest correlation of tumor occurrence in monozygotic twins, which indicated that shared “modifier genes” rather than NF1 mutations per se also played an important role on neurofibroma occurrence.5

In sporadic neurofibroma or Schwannoma, even less is known about the malignant transformation process. Mutations leading to the loss of function of TP53, RB1 and deletions of the CDKN2A gene have been reported in both NF1-associated and sporadic MPNSTs suggesting that a series of mutations of tumor suppressor genes contributes to tumorigenesis and subsequent malignant transformation.5–8 In addition to tumor suppressor gene mutations, oncogenic mutations in platelet-derived growth factor receptor alpha (PDGFR-α), as well as gene amplification of epidermal growth factor receptor (EGFR) and hepatocyte growth factor (HGF) have been reported in MPNSTs, although these mutations are found at very low frequency.7,9,10 Taken together, these studies suggest that there is significant genetic heterogeneity in the initiation and progression of MPNSTs.

Currently, several MPNST cell line-based gene expression analyses have been used to identify gene expression signatures characteristic of MPNST,11,12 but the knowledge of the genetic background of these cell lines is quite limited. A detailed characterization of the genetic alterations in such cell lines will contribute to the understanding of MPNST tumorigenesis and decipher the gene expression alterations derived from microarray gene expression data. Moreover, the determination of actionable oncogenic mutations13 in MPNST cell lines may provide insight into rational MPNST therapeutics and drug discovery for the clinic. We therefore set out to determine whether the most frequent activating oncogene mutations found in human cancers were present in these MPNST cells. Mutational analysis of neurofibroma was carried out to investigate whether additional genetic alterations in any known oncogenes led to the development of MPNST. Here, we present the first report of oncogene mutation analysis of the most frequent 238 mutations in 19 oncogenes using mass spectroscopy based analysis among 5 MPNST cell lines.

Materials and Methods

Cell lines and tissue culture

Human MPNST ST88-14 cells (a generous gift from T. Glover, University of Michigan, Ann Arbor, MI, USA) and STS26T cells (a generous gift from D. Scoles, Cedars-Sinai Medical Center, Los Angeles, CA, USA) were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with
5% fetal bovine serum (HyClone Laboratories, Logan, UT, USA). T265 cells (a generous gift from G. De Vries, Hines VA Hospital, Hines, Illinois USA) were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 5% fetal bovine serum. sNF96.2 and sNF02.2 cell lines were purchased from American Type Culture Collection and cultured in DMEM supplemented with 10% fetal bovine serum. Normal human Schwann cell line HSC361 (a kind gift from Patrick M. Wood, University of Miami Miller School of Medicine, Miami, FL, USA) was cultured in DMEM supplemented with 10% FBS, 2 µM forskolin, and 10 nM heregulin. Cell lines were checked periodically for myco-plasma with Venor GeM Mycoplasma Detection Kit (Sigma, St. Louis, MO, USA). Cultures were propagated for no more than 3 months.

Western blot analysis
Cultures at 30% to 80% confluence were washed 3 times with ice-cold PBS, scraped and pelleted at 1,000 rpm for 5 min. Cell pellets were lysed with RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.5% deoxycholic acid, 0.1% SDS, 50 mM Tris–Cl, pH 8.0) supplemented with 2% protease inhibitor cocktail, 1% PMSF, 1 mM Na2VO4, 1 mM Na2P2O7·10H2O, and 1 mM NaF. Secondary antibodies were conjugated to IRdye infrared dyes (Rockland Inc, Gilbertsville, PA, USA). Signal was detected and the bands were quantified using the Odyssey infrared imaging system and software (Licor Biosciences, Lincoln, NE, USA). Antibodies used in these experiments were rabbit polyclonal anti-neurofibromin (#sc-67, Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA), mouse monoclonal anti-phospho-ERK1,2 (#9106, Cell Signaling), and mouse monoclonal anti-a-tubulin (#T5168, Sigma–Aldrich, St. Louis, MO, USA). Neurofibromin in cell lysates was detected by 8% SDS polyacrylamide gel electrophoresis (SDS-PAGE). Phosphorylated Erk1/2 was detected on 10% SDS-PAGE. 80 µg protein lysate was loaded in each well, and PDVF membrane was used for protein transfer.

Oncogenomic profiles based on point mutation analysis
DNA was extracted from MPNST cell lines grown in culture using the DNeasy blood and tissue kit (Qiagen, catalog 69504). Point mutation analysis was performed using the mass-spectroscopy based MassArray system developed by Sequenom (San Diego, CA, USA). In this study, we employed the Sequenom OncoCarta Panel v1.0. This mutational panel interrogates 238 mutations in 19 oncogenes (Table 1). These mutations include small indels and single base pair changes that result in non-synonymous coding mutations previously reported in human cancers.13 The assays are multiplexed into 24 reactions, each of which requires 20 ng of input DNA. Briefly, an initial PCR reaction is performed to amplify a small region of DNA (between ~80 to 120 base pairs) which includes the potential point mutation site. Next, a specific oligonucleotide primer with at least 10 bases of complementary DNA binds immediately upstream of the mutation site and is extended by one base into the potential mutation site. The oligonucleotide primers are subsequently separated on a matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometer which is able to quantitatively discern the specific nucleotide that was extended. This method can reproducibly detect mutations at a frequency as low as 10% within a given sample.

Results
Five different MPNST cell lines were used to detect oncogene mutations according to the OncoCarta Panel V1.0. ST88-14, T265, sNF96.2 and sNF02.2 are NF1-associated MPNSTs with either undetectable or extremely low neurofibromin protein levels as shown by western blot analysis (Fig. 1). STS26T cells were derived from a sporadic MPNST and have functional neurofibromin as did normal human Schwann cells (HSC361) which were used as a positive control. Cytogenetic characterization of ST88-14 cells has shown that the NF1 locus has been deleted from one allele on chromosome 17 while the gene on the remaining allele exhibits greatly reduced transcriptional activity.14 A heterozygous nonsense mutation in NF1 (C910T) in codon 304 (R304X) of exon 7 was also reported in ST88-14.15 In the T265 cell line, no NF1 mutation has been reported, and the neurofibromin was hardly detectable (Fig. 1). In the sNF96.2 cell line, no NF1 mutation has been reported, and the neurofibromin was hardly detectable (Fig. 1). The sNF96.2 cell line was derived from a recurrent mass associated with nerve tissue and diagnosed as MPNST in an NF1 patient. This line has an abnormal karyotype and complete loss of heterozygocity with no detectable DNA from the wt-NF1 allele.16
The sNF02.2 cell line was derived from a lung metastasis MPNST in an NF1 patient. A very weak full length NF1 band was observed in these two cell lines (Fig. 1). The STS26T cell line was derived from a sporadic malignant Schwannoma, a type of soft tissue sarcoma. This cell line has a wild type neurofibromin but p53 expression was completely absent. Increased MAPK activity has been reported in NF1 patients. We confirmed this increased MAPK activity by testing the phosphorylation state of Erk1/2 in all the MPNST cell lines in our study. All the MPNST cell lines exhibited more phosphorylated Erk1/2 than the normal HSC361 cell line. However, the relative intensity of Erk1 and Erk2 varied among the different cell lines. Notably, even with functional neurofibromin, the phosphorylated Erk1/2 in STS26T was significantly higher than the normal HSC361 cells which emphasizes the indispensable role of MAPK pathway activation in NF1-related MPNSTs.

### Table 1. Mutations assayed for each of the 19 Genes in the Oncocarta v1.0 Mutation Panel. A total of 238 mutations were assayed.

| Gene name | Mutation sites checked |
|-----------|------------------------|
| ABL-1     | G250E, Q252H, Y253H, Y253F, E255K, E255V, D276G, F311L, T315I, F317L, M351T, E355G, F359V, H396R |
| AKT-1     | V461L, P388T, L357T, E319G, V167A, Q43X, E17del |
| AKT-2     | S302G, R371H |
| BRAF      | G464R, G464V/E, G466R, F468C, G469S, G469E, G469A, G469V, G469R, D594V/G, F595L, G596R, L597S, L597R, L597Q, L597V, T599I, V600E, V600K, V600R, V600L, K601N, K601E |
| CDK-4     | R24C, R24H |
| EGFR      | R108K, T263P, A289V, G598V, E709K/H, E709A/G/V, G719S/C, G719A, M766_A767insAI, S768I, V769_D770insASV, V769_D770insCV, D770_N771->AGG/V769_D770insASV/V769_D770insAV, D770_N771insG, N771_P772->SVDRN, P772_H773insV, H773->NYP, H773_V774insNPH/PH/H, V774_C775insHV, T790M, L858R, L861Q, E746_T751del, E746_A750del, E746_T751del, E746_T751del, S752D, L747_E749del, L747_T750del, L747_S752del, L747_T751del, L747_S752del, P753S, A750P, T751A, T751P, T751I, S752I/F595L, L597S, L597Q, L597V, V600E, V600K, V600R, V600L, K601N, K601E |
| ERBB2     | L755P, G776S/LC, G776VC/VC, A775_G776insYMA, P780_Y781insGSP, P780_Y781insGSP, S779_P780insVGS |
| FGFR-1    | S125L, P252T |
| FGFR-3    | G370C, Y373C, A391E, K650Q/E, K650T/M |
| FLT-3     | I836del, D835H/Y |
| JAK-2     | V617F |
| KIT       | D52N, Y503_F504insAY, W557R/G, V559D/A/G, V559I, V560D/G, K550_K558del, K558_V560del, K558_E562del, V559del, V559_V560del, V560del, V560del, Y570_L576del, E561K, L576P, P585P, D579del, K642E, D816V, D816H/Y, V825A, E839K, M552L, Y568D, F584S, P551_V555del, Y553_Q556del |
| MET       | R970C, T992I, Y1230C, Y1235D, M1250T |
| PDGFRa    | V561D, T674I, H808L, D846Y, N870S, D1017N, D842_H845del, I843_D846del, S666_E571->K, I843_S847->T, D842V |
| PIK3CA    | R88Q, N345K, C420R, P539R, E542K, E545K, Q546K, H701P, H1047R/L, H1047Y, R38H, C901F, M1043I |
| H-RAS     | G12V/D, G13C/R/S, Q61H/H, Q61L/R/P, Q61K |
| K-RAS     | G12C, G12R, G12S, G12V, G12D, G12A, G12F, G13V/D, A59T, Q61E/K, Q61L/R/P, Q61H/H |
| N-RAS     | G12V/A/D, G12C/R/S, G13V/A/D, G13C/R/S, A18T, Q61L/R/P, Q61H, Q61E/K |
| RET       | C634R, C634W, C634Y, E632_L633del, M918T, A664D |

![Figure 1](Image)  
Neurofibromin and Phos-ERK1/2 expression in the cell lines.
and acceptable cost. In this study, we assayed the 238 most frequent mutations in 19 commonly activated oncogenes. This panel covered 90%–99% of the mutation prevalence reported thus far in the 19 oncogenes. All 238 mutation sites in the assayed oncogenes were determined to harbor only wild-type sequences in all 4 NF1-defective MPNST cell lines or STS26T (NF1-wild type) using the OncoCarta Panel V1.0 (Table 1).

**Discussion**

MPNST is a rare malignant tumor with poor prognosis, accounting for 3%–10% of all soft tissue sarcomas. Microarray studies failed to distinguish the NF1-associated and sporadic form of MPNST which indicates accumulated aberrant gene regulation is common in this kind of tumor. It is generally believed that MPNST probably comprises multiple distinct tumors sharing similar histological manifestations and therefore may arise from heterogeneous mechanisms of tumorigenic transformation. It is a consensus that NF1-associated neurofibroma is derived from NF1−/− Schwann cells and that the NF1+/− haplo-deficient cells within the tumor microenvironment contribute to malignant transformation. However, the key biological events occurring during MPNST development are not clear. Schwannoma is also a benign peripheral nerve sheath tumor and 1% can undergo malignant conversion such as the STS26T cell line. Although TP53 mutations appear to be more associated with the sporadic form, it is not known whether other genetic alterations contribute to the malignant transformation of these benign tumors. Indeed, four of the cell lines in this study are known to be TP53 wild-type and these are the cell lines derived from NF1−/− NF1-associated MPNSTs (ST88-14, T265, sNF96.2 and sNF02.2). Only the sporadic MPNST-derived cell line STS26T is TP53 null. By analyzing potential oncogene mutations, we sought to identify whether such genetic alterations play a role in the evolution of MPNSTs.

Among the 19 oncogenes we investigated for activating mutations, only 4 genes have been reported to be mutated in MPNST tumors. Specifically, activating point mutations have been found at a very low frequency in BRAF (1/83 tumors tested) Kras (1/98), NRAS (1/33), and PDGFRα (2/61) in the COSMIC database. Furthermore, gene amplification of EGFR, ERBB2 and c-KIT have also been reported previously. In addition, among the 19 oncogenes we assayed, no activating point mutations were found in the following: EGFR (81 tumor samples analyzed), ERBB2 (40), HRAS (33), KIT (38), PIK3CA (23) and RET (4) (COSMIC Database).

The results presented here suggest that oncogene mutation related effects were not necessary in the formation of MPNSTs, especially in the context of hyperactive Ras due to NF1 loss. In the NF1-associated MPNSTs, the constitutively active Ras pathway provides strong pro-survival signals through its downstream Raf-MEK-MAPK and PI3K-AKT signaling pathway. These activated pathways may abrogate the selective pressures against mutations in oncogenes such as AKT1, AKT2, BRAF, and PI3K during tumorigenesis. This may explain why the common oncogene mutations in cancer were not observed in this study. On the other hand, the absence of oncogene mutations also suggests that elevated Ras activation due to NF1 deficiency in an NF1 haplo-insufficient microenvironment may be sufficient to initiate the cells and microenvironment to facilitate the pro-survival of the NF1 mutation-bearing Schwann cells to circumvent the anti-cancer mechanism and finally develop malignancy. For the sporadic MPNST, limited availability of tissue has made it more difficult to study than its NF1-associated counterpart. Here, we first explored possible oncogene mutations in the STS26T cell line, and the results indicated the mechanism giving rise to the sporadic MPNST is more complicated than the known changes in pathways downstream of Ras or other oncogenes.

It is possible that potential mutations were not known or covered by our panel of 238 assays in this study. However, based on the COSMIC database and our study, extra oncogene activation is rarely reported in NF1 patients and MPNST cell lines. This study cannot rule out other regulatory mechanisms such as epigenetic modification of the expression of other key cellular regulatory pathways, however. In the NF1-associated MPNSTs, our data suggests that hyperactive Ras due to NF1 loss of function provides a sufficient impetus to malignancy. The NF1 haplo-deficient cells and the microenvironment are involved in the final selection process of tumor
formation, which partially explains the latency of MPNST in NF1 patients.

Acknowledgment
This work was supported by DOD W81XWH-08-20160 and Barbara and Fred Erb Endowed Chair in Cancer Genetics to MAT.

Disclosures
Author(s) have provided signed confirmations to the publisher of their compliance with all applicable legal and ethical obligations in respect to declaration of conflicts of interest, funding, authorship and contributorship, and compliance with ethical requirements in respect to treatment of human and animal test subjects. If this article contains identifiable human subject(s) author(s) were required to supply signed patient consent prior to publication. Author(s) have confirmed that the published article is unique and not under consideration nor published by any other publication and that they have consent to reproduce any copyrighted material. The peer reviewers declared no conflicts of interest.

References
1. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311–4.
2. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role in tumor environment. Science. 2002; 296:920–2.
3. Carroll SL, Ratner N. How does the Schwann cell lineage form tumors in NF1? Glia. 2006;58:1590–605.
4. Courtois-Cox S, Genther Williams SM, Reczek EE, et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer. 2006;10:459–72.
5. Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet. 1993;53:305–13.
6. Birindelli S, Perrone F, Oggiomoni M, et al. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest. 2001;81:833–44.
7. Manitpragada KK, Sparlock G, Kluwe L, et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res. 2008;14:1015–24.
8. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, et al. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 1999;155:1879–84.
9. DeChue JE, Heffelfinger S, Benvenuto G, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest. 2000;105:1233–41.
10. Holtkamp N, Okudeuc AF, Mucha J, et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis. 2006;27:664–71.
11. Lee PR, Cohen JE, Tendi EA, et al. Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells. Neuron Glia Biol. 2004;1:135–47.
12. Miller SJ, Rangwala F, Williams J, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res. 2006;66:2584–91.
13. Thomas RK, Baker AC, DeBiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347–51.
14. Reynolds JE, Fletcher JA, Lyleth C, Nie L, Morton CC, Diehl SR. Molecular characterization of a 17q11.2 translocation in a malignant schwannoma cell line. Hum Genet. 1992;90:450–6.
15. Barkan B, Starinsky S, Friedman E, Stein R, Kloor Y. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res. 2006;12:5533–42.
16. Fieber LA, Gonzalez DM, Wallace MR, Muir D. Delayed rectifier K currents in NF1 Schwann cells. Pharmacological block inhibits proliferation. Neurobiol Dis. 2003;13:136–46.
17. Dahlberg WK, Little JB, Fletcher JA, Suit HD, Okunieff P. Radiosensitivity in vitro of human soft tissue sarcoma cell lines and skin fibroblasts derived from the same patients. Int J Radiat Biol. 1993;63:191–8.
18. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992;356:713–5.
19. Grohmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97:340–9.
20. Watson MA, Perry A, Tihan T, et al. Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol. 2004;14:297–303.
21. Li Y, Rao PK, Wen R. Notch and Schwann cell transformation. Oncogene. 2004;23:1146–52.
22. Lopez G, Torres K, Liu J, et al. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011;71:185–96.
23. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39:D945–50.
24. Bottilo I, Alquist T, Brekke H, et al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol. 2009;217:693–701.
25. Perrone F, Da Riva L, Orsenigo M, et al. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol. 2009;11:725–36.
26. Tawbi H, Thomas D, Lucas DR, et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist. 2008;13:459–66.
27. Gill S, Stratton MR, Patterson H, et al. Detection of transforming genes by transfection of DNA from primary soft-tissue tumours. Oncogene. 1991;6:1651–6.
28. Jin Y, Shima Y, Furu M, et al. Absence of oncogenic mutations of RAS family genes in soft tissue sarcomas of 100 Japanese patients. Anticancer Res. 2010;30:245–51.
29. Loughrey MB, Trivett M, Beshay V, et al. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib. Histopathology. 2006;49:52–65.
30. Perry A, Kunz SN, Fuller CE, et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol. 2002;61:702–9.
Publish with Libertas Academica and every scientist working in your field can read your article

“I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely.”

“The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I’ve never had such complete communication with a journal.”

“LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought.”

Your paper will be:
- Available to your entire community free of charge
- Fairly and quickly peer reviewed
- Yours! You retain copyright

http://www.la-press.com